Restructuring-related charges, net of tax $25
Litigation-related charges $334
Income tax benefit (d) (68)
Litigation-related charges, net of tax $266
Divestiture-related (gains) losses:
Gain on sale of investments (c) $(15)
Loss on assets held for sale $352
Income tax benefit (d) (11)
Divestiture-related (gains) losses, net of tax $(26) $352
Intangible asset impairment charges:
Intangible asset impairment charges $155
Income tax benefit (d) (26)
Intangible asset impairment charges, net of tax $129
Amortization expense $131 $155
Income tax benefit (d) (35) (19)
Amortization expense, net of tax $96 $136
(a) Recorded $8 million to selling, general and administrative expenses
and $2 million to cost of products sold.
(b) Recorded $4 million to cost of products sold; $9 million to selling,
general and administrative expenses; $1 million to research and
development expenses; and $20 million to restructuring charges.
(c) Recorded to other, net.
(d) Amounts are tax effected at the Company's effective tax rate, unless
the amount is a significant unusual or infrequently occurring item in
accordance with FASB Interpretation No. 18, "Accounting for Income
Taxes in Interim Periods."
An explanation of the Company's use of these non-GAAP measures is
provided at the end of this document.
|SOURCE Boston Scientific Corporation|
Copyright©2008 PR Newswire.
All rights reserved